🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our paper, published last month in Cancer Cell and highlighting pre-clinical & MOA data for RBN-2397, our small molecule inhibitor of PARP7, was recognized by Cancer Discovery & captured in its Research Watch section. For the abstract: bit.ly/3A4TAF5 #oncology Cancer Discovery

We’re pleased to announce the promotions of Heike Keilhack, Ph.D., to Chief Scientific Officer and Kevin Kuntz, Ph.D., to Chief Drug Development Officer. Both have been integral to advancing our novel therapeutics. Read more: ribontx.com/ribon-therapeu… #Biotech #Leadership

We’re thrilled to be named a 2021 #Fierce15 Winner by FierceBiotech! The team at Ribon is dedicated to driving our innovative pipeline of therapeutics targeting stress support pathways for patients with #cancer and #inflammatory diseases. Learn more: ribontx.com/ribon-therapeu…

Members of our management team are looking forward to a productive time this week at the SVB Leerink Biopharma Private Company Connect. We hope to see you there! #biotech

We’d like to thank @Biotech2050pod for hosting our Chief Scientific Officer, Heike Keilhack, on this week’s podcast. Use the below link to hear more about our incredible science from one of our own! Listen here: bit.ly/3mbmRdf #biotech #oncology #inflammation

The Ribon team is thrilled to be participating at the Piper Sandler 33rd Annual Virtual Healthcare Conference next week. We hope to see you there! #biotech

Thank you to Healthcare Businesswomen's Association New England Region for last week’s fireside chat discussion with our CEO, Vicky Richon. We support HBA’s mission to further the advancement and impact of women in the business of healthcare. Learn more: bit.ly/3dCo7B4

ICYMI, check out this article written by our CSO, Heike Keilhack, as she shares her unique insights on the many hats she wears in her crucial role at Ribon. Read more here: linkedin.com/pulse/reflecti… #biotech #leadership

We are thrilled to welcome Prakash Raman, Ph.D., as our new President and CEO. Dr. Raman joins our team during an exciting time of growth and execution. Read more here: bit.ly/34OoV57 #biotech #leadership

Today we announced the initiation of our Phase 1 study of RBN-3143. This study marks our second first-in-class program in the clinic and our first for the treatment of inflammatory disease. Read more here: bit.ly/3D288YY #biotech #leadership

We are pleased to initiate our Phase 1b/2 study of RBN-2397 in combination with pembrolizumab in patients with squamous cell carcinoma of the lung. RBN-2397 is a PARP7 inhibitor being evaluated for the treatment of cancer. Read more here: bit.ly/36AyFAI #oncology

Yesterday, members of our team presented clinical and preclinical data for RBN-2397, our lead program for oncology, at the AACR 2022 Annual Meeting. Read more here: bit.ly/3KCD0Cr #biotech #oncology

We are pleased to receive additional financing from our partner, K2 HealthVentures, as we advance clinical development of RBN-2397 and RBN-3143 and evaluate multiple preclinical programs leveraging stress support pathway biology. #biotech

Join us in celebrating Pride Month this June! At Ribon, we are committed to not only fostering a diverse and inclusive workplace, but also a diverse and inclusive world. Our unique differences are what make us strong. #PrideMonth #HappyPride

We are thrilled to welcome Gary Sutton as our new Chief Business Officer. Gary brings over 18 years of experience in the BioPharma Industry and will be an invaluable member of our team. Read more about our management team here: bit.ly/3NEejXQ #biotech #leadership

This #Juneteenth, join us in reflection and celebration of Black culture, heritage and freedom. At Ribon, we strive to make a positive impact in our communities and that starts with each of us!

Check out our recent publication in ImmunoHorizons highlighting the potential of PARP14 inhibition to attenuate allergic lung inflammation. To read more about this and our other exciting scientific publications and presentations, click here: bit.ly/3cbHQu0 #biotech

We are pleased to share new preclinical data presented at the European Respiratory Society International Congress 2022 demonstrating the potential of RBN-3143 as a PARP14 inhibitor across a range of inflammatory models. Read more here: bit.ly/3KOSRyu #PARP14 #biotech

The Ribon team looks forward to a productive time at the upcoming Citi and Morgan Stanley healthcare conferences. We hope to see you there! #biotech #leadership

We are pleased to announce that Boehringer Ingelheim has agreed to acquire our pre-clinical CD38 program, which Ribon developed from target and lead discovery through lead optimization using our proprietary BEACON+ platform. Read more here: bit.ly/3Vok3c8 #CD38 #biotech